NEWS
March 4, 2021
S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
December 1, 2019
Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
January 4, 2019
S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
January 4, 2019
S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
December 20, 2018
S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
April 5, 2016
MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
February 19, 2016
Pharmaceutical Processing | In Development: HSDD Treatment for Women
February 19, 2016
PM360 | Will Lorexys Succeed Where Addyi Flopped?
December 8, 2015
S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
COMPANY
ABOUT US
MANAGEMENT
BOARD OF DIRECTORS
MEDICAL ADVISORY BOARD
PIPELINE
OREXA
LOREXYS
S1B-307
S1B-3006
A New Vision for addressing Sexual Wellness
SEXUAL DYSFUNCTION R&D
SCIENTIFIC PUBLICATIONS
PARTNERING
NEWSROOM
PRESS RELEASES
MEDIA COVERAGE
INVESTORS
LOGIN
CONTACT US
DUE TO COVID-19
We plan to participate virtually in other 2021 events when possible
Maxim Group ⌇ M-Vest: Late Stage Innovations in Women’s Health
March 4, 2021 M-Vest.com